February 5, 2026 -
Pittsburgh, USA, February 05, 2026 – MolecuLight today announced that the United States International Trade Commission (“ITC”) has formally instituted an investigation into the SnapshotGLO product, following the complaint previously filed by MolecuLight Corp and MolecuLight Inc. The investigation will examine whether the SnapshotGLO product infringes U.S.
… Read MoreJanuary 29, 2026 -
Pittsburgh, USA, January 29, 2026 – MolecuLight today announced that its MolecuLightDX® wound measurement has been qualified by the U.S. Food and Drug Administration (FDA) as a Medical Device Development Tool (MDDT). The FDA’s MDDT program qualifies select, scientifically validated tools for use in medical device development
… Read MoreJanuary 13, 2026 -
Pittsburgh, PA, USA – January 13, 2026 – MolecuLight Corp. and MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria and digital wound measurement, today announced that it has filed a complaint with the United States International Trade Commission (ITC) requesting
… Read MoreDecember 16, 2025 -
Tissue Analytics moves toward a unified, AI-powered imaging experience that seamlessly connects data from point-of-care devices to EHR workflows
PITTSBURGH, PA – Dec. 16, 2025 – Net Health today announced the platform integration of MolecuLight with Tissue Analytics, its AI-powered mobile wound imaging and analytics solution. This enables
… Read MoreDecember 9, 2025 -
Streamlined integration enhances wound care by combining bacterial detection, digital wound measurements, and thermal imaging with direct Oracle Health Foundation EHR connectivity
Pittsburgh, USA, December 9, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment and an Oracle partner, today announced the
… Read MoreNovember 13, 2025 -
Pittsburgh, USA – November 13, 2025 – MolecuLight Corp., a global leader in point-of-care fluorescence imaging for wound assessment, is proud to announce the publication of a landmark international consensus report, developed by leading experts in wound care and surgery from across the United States. The report,
… Read MoreSeptember 4, 2025 -
Pittsburgh, USA – September 4, 2025 – MolecuLight Corp., the global leader in point-of-care fluorescence imaging for wound care, announces continued innovation in wound care technology and its presence at the Symposium on Advanced Wound Care (SAWC) Fall 2025, September 3–6 in Las Vegas, NV. Attendees can
… Read MoreAugust 27, 2025 -
PITTSBURGH, USA and TAIPEI, TAIWAN, August 27, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, together with its Taiwanese distributor, Healtdeva Company Ltd., today announced the publication of the largest-ever randomized controlled trial (RCT) on its technology. Independently conducted and published
… Read MoreJuly 18, 2025 -
Pittsburgh, USA – July 18, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, today announced its participation in the National Medical Association (NMA) Annual Convention and Scientific Assembly, being held from July 19-23, 2025, in Chicago, IL. Attendees are invited to
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.